Navigation Links
Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
Date:10/2/2007

AstraZeneca's Seroquel Emerges as the Antipsychotic of Choice in All Lines

of Therapy, According to a New Report from Decision Resources

WALTHAM, Mass., Oct. 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient treatment for bipolar disorder varies depending on doctor specialty. According to the new report entitled Treatment Algorithms in Bipolar Disorder, psychiatrists and PCPs overall approach to treating bipolar disorder patients differs significantly. Nearly all surveyed psychiatrists currently prescribe the three American Psychological Association (APA) recommended first-line monotherapies for bipolar mania: lithium (99 percent), valproic acid (95 percent) and atypical antipsychotics, such as AstraZeneca's Seroquel (95 percent), as well as the recommended treatment for bipolar depression (GlaxoSmithKline's Lamictal, 96 percent). Seventy-nine percent of surveyed PCPs currently prescribe lithium and 81 percent prescribe Seroquel; however only half of PCPs currently prescribe valproic acid or Lamictal. When treating depressive symptoms, psychiatrists follow APA guidelines and choose Lamictal as their key agent; PCPs opt for antidepressants first line.

Physicians have a wealth of bipolar drugs to choose from, especially among the antipsychotics, and not enough clinical data to differentiate their use. Manufacturers that are able to differentiate their drugs and communicate these factors to physicians, particularly to PCPs, will see the largest increases in share. "Physicians overwhelmingly agree that there is a strong need for clinical trial data," said Nicole Westphal, Ph.D. analyst at Decision Resources. "In addition to safety, trials that demonstrate an agent's efficacy in treating bipolar depression or that demonstrate a drug's effectiveness as a well-tolerated maintenance treatment have the greatest potential to alter physician use."

The report also finds that Seroquel has gained ground among both psychiatrists and PCPs as a first-line monotherapy and maintenance treatment. Seroquel captures 14.5% patient share first line, up 13.1% from just two years ago. Seroquel will continue to acquire patient share in all lines of therapy, largely owing to its first-in-class status among the antipsychotics to treat both mania and depression. Janssen's Risperdal and Eli Lilly's Zyprexa suffered the greatest losses, losing a combined 11.9% patient share first line over the same time period.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:

-- Summary of U.S. medical practice based on interviews with leading

experts in the field

-- Qualitative diagnosis/referral/treatment algorithm for the United

States

-- Drug usage by lines of therapy (1st, 2nd, 3rd line)

-- Discussion of key freeform combinations by lines of therapy

-- Product share (class and specific compound level) within each line of

therapy (1st, 2nd, 3rd line)

-- Progression of therapy from key 1st line products

-- Pathway to key therapies from previous therapies

-- Qualitative analysis of 2-year forecast incorporating upcoming

launches, changes in reimbursement, etc.

About Decision Resources

Decision Resources, Inc., (http://www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sensitive detection of tumor cells in peripheral blood of carcinoma patients by a reverse transcription PCR method
2. Quantitation of GAD67 Gene Expression in Prefrontal Cortex of Schizophrenia Patients Using the iCycler iQ Detection System and Molecular Beacons, Rev A
3. Milwaukee takes another step in electronic patient data exchange
4. What patients want: A story of choice, clinical trials & evidence-based medicine
5. GE partner allows real-time access to patient data
6. Sun, TeraMedica solution aimed at doctor-patient relationship
7. Interview: Dr. William Yasnoff on patient-centric IT
8. Video game technology could improve physician-patient interactions
9. GE and Intermountain want to streamline nationwide patient data
10. Human factors and IT: Designing for patient safety
11. The challenges of maintaining patient privacy and delivering secure clinical information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
Breaking Biology Technology:
(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):